On April 3, 2014, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) successfully issued an aggregate of 67,214,000 new H Shares at the placing price of HK$26.51 to no fewer than six but no more than 10 buyers. The net proceeds from the placing amounted to approximately HK$1.76 billion.

Fosun Pharma was established in 1994 and was listed on the Shanghai Stock Exchange in August 1998 and on the Main Board of the Stock Exchange of Hong Kong in October 2012. It is a leading healthcare company in China.

The net proceeds will be used to pay off debts, replenish operating capital and finance potential domestic or overseas acquisitions.

AllBright partners Lawrence Zhu, Ark Bao, Shen Cheng and associate Mandy Wang formed the Chinese legal team for the placing agents, UBS, J.P. Morgan and CCB International.